Scarica l'app Stockscreener
18.63
0.76%
0.14
Dopo l'orario di chiusura:
19.38
0.75
+4.03%
Precedente Chiudi:
$18.49
Aprire:
$19.86
Volume 24 ore:
1.35M
Relative Volume:
0.78
Capitalizzazione di mercato:
$1.89B
Reddito:
$54.55M
Utile/perdita netta:
$-193.57M
Rapporto P/E:
-6.4464
EPS:
-2.89
Flusso di cassa netto:
$-181.86M
1 W Prestazione:
-1.79%
1M Prestazione:
-13.23%
6M Prestazione:
+52.58%
1 anno Prestazione:
-4.51%
Intervallo 1D:
$18.35
$19.92
Intervallo di 1 settimana:
$16.98
$19.92
Portata 52W:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
18.63 | 1.87B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
How Nurix Therapeutics Inc. stock compares to market leadersShare Buyback & Trade Opportunity Analysis - ulpravda.ru
Will Nurix Therapeutics Inc. stock beat EPS estimates2025 Major Catalysts & Precise Swing Trade Entry Alerts - ulpravda.ru
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpStill a Buy? - MarketBeat
Why Nurix Therapeutics Inc. stock appeals to analystsJuly 2025 Recap & Fast Moving Stock Trade Plans - ulpravda.ru
What 18 Analyst Ratings Have To Say About Nurix Therapeutics - Benzinga
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Yahoo Finance
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Insider Monkey
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance
Should I hold or sell Nurix Therapeutics Inc. stock in 20252025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Stock Analysis: Is Nurix Therapeutics Inc. stock a defensive play in 2025Quarterly Performance Summary & AI Forecasted Entry and Exit Points - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Does New NX-5948 Phase 2 Dose Selection Change The Bull Case For Nurix Therapeutics (NRIX)? - simplywall.st
Is Nurix Therapeutics Inc. stock a defensive play in 2025Index Update & Stepwise Entry/Exit Trade Alerts - Улправда
Will Nurix Therapeutics Inc. stock gain from lower inflationEarnings Trend Report & Reliable Price Breakout Alerts - Улправда
Sell Signal: Is Nurix Therapeutics Inc. stock a defensive play in 2025 - Улправда
Nurix Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
Officer Ring Sells 3,760 ($67.3K) Of Nurix Therapeutics Inc [NRIX] - TradingView — Track All Markets
Nurix Therapeutics (NRIX) Chief Legal Officer reports option exercise and stock sales - Stock Titan
Why Nurix Therapeutics Inc. stock could outperform in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4%Here's What Happened - MarketBeat
Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients - TipRanks
Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Given New $30.00 Price Target at Wells Fargo & Company - MarketBeat
Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025 - ts2.tech
Nurix Therapeutics, Inc. $NRIX Shares Purchased by Nikko Asset Management Americas Inc. - MarketBeat
Redmile Group LLC Lowers Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Optimistic Investors Push Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Up 48% But Growth Is Lacking - 富途牛牛
Nurix prices 24.5M shares at $10.21 in underwritten registered offering - MSN
Nurix Therapeutics price target raised to $31 from $28 at HC Wainwright - MSN
Cathie Wood Reduces Iridium Holdings While Adding Biotech Stock Nurix Therapeutics - parameter.io
Why Cathie Wood Just Sold Millions in Iridium and Bought This Biotech Stock - CoinCentral
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday - Investing.com
What insider trading reveals about Nurix Therapeutics Inc stockMarket Activity Report & Risk Controlled Daily Plans - moha.gov.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 at Mizuho - MarketBeat
Nurix stock price target raised to $31 from $28 at H.C. Wainwright - Investing.com UK
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):